145,000 stock options granted to Oncolytics (ONCY) COO McAdory

Rhea-AI Filing Summary

Oncolytics Biotech Inc. reported that Chief Operating Officer John Bearden McAdory received a grant of stock options as part of his compensation. He was awarded options covering 145,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.

The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as he continues in service or employment on each vesting date. The options expire on June 1, 2036. This is a derivative award, not an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McAdory John Bearden

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	145,000	$0.00	--

Holdings After Transaction: Stock Option — 145,000 shares (Direct, null)

Footnotes (1)

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Stock options granted: 145,000 options Exercise price: $1.06 per share Underlying common shares: 145,000 shares +2 more

5 metrics

Stock options granted 145,000 options Grant to COO on June 1, 2026

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Underlying common shares 145,000 shares Shares purchasable upon option exercise

Option expiration date June 1, 2036 End of exercise period for this grant

Vesting schedule 3 equal annual installments First vesting on June 1, 2027

Key Terms

Stock Option, exercise price, vests in three equal annual installments, expiration date

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments"

expiration date financial

"expiration_date": "2036-06-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McAdory John Bearden

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		145,000		(2)	06/01/2036	Common Shares	145,000	$0	145,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ONCY COO John Bearden McAdory report in this Form 4?

He reported receiving a stock option grant for 145,000 common shares of Oncolytics Biotech Inc. This is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.

What is the exercise price of the ONCY options granted to the COO?

The options have an exercise price of $1.06 per share, which equals the closing price of Oncolytics’ common stock on the Nasdaq Capital Market on June 1, 2026, the date of grant, according to the filing’s footnote disclosure.

How many ONCY shares underlie the COO’s new stock options?

The grant covers 145,000 underlying common shares of Oncolytics Biotech Inc. These shares are not issued immediately; they become purchasable only if and when the options vest and are exercised in the future by the reporting person.

When do the new ONCY stock options for the COO vest?

The stock options vest in three equal annual installments, with the first tranche vesting on June 1, 2027. Each installment requires the COO’s continued service or employment on the applicable vesting date, as described in the footnote.

When do the ONCY COO’s stock options expire?

The options are scheduled to expire on June 1, 2036, giving the COO a multi-year window to exercise them after vesting. After the expiration date, any unexercised portion of the grant will no longer be exercisable under the award terms.

Is this ONCY Form 4 a stock purchase or sale in the market?

No. The Form 4 reports a grant of stock options, categorized as a derivative award. It is not an open-market purchase or sale of common shares; instead, it provides the right to buy shares later at $1.06 per share.